Skip to main content

12.07.2016 | SCLC | Onlineartikel

Exploring established and novel EGFR-directed agents

The phase IIb LUX-Lung 7 trial was a head-to-head comparison of the second- generation ErbB family blocker afatinib and the first-generation reversible EGFR TKI gefitinib in patients with treatment-naïve, EGFR-mutation-positive, advanced (stage IIIB/IV) adenocarcinoma of the lung. According to the primary analysis, patients treated with afatinib derived significant PFS, ORR and time-to-treatment-failure benefits compared to those who received gefitinib [1]. The OS data are currently immature.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weiterführende Themen